Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia
Jonathan Hoggatt,1 Tiffany A Tate,1 Louis M Pelus2 1Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA; 2Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, USA Abstract: Chemotherapy, irradiation, and other age...
Enregistré dans:
Auteurs principaux: | Hoggatt J, Tate TA, Pelus LM |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2015
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/d1e3f98579804b9c81d3d3eb9b386d6e |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia [Corrigendum]
par: Hoggatt J, et autres
Publié: (2015) -
Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients
par: Guariglia R, et autres
Publié: (2016) -
Review on lipegfilgrastim
par: Gasparic M, et autres
Publié: (2015) -
Biosimilars in the management of neutropenia: focus on filgrastim
par: Caselli D, et autres
Publié: (2016) -
Lamotrigine‐induced neutropenia after high‐dose concomitant initiation with phenytoin
par: Muhammad Salem, et autres
Publié: (2021)